Sunshine Biopharma, Inc. (NASDAQ:SBFM) Stock Short Interest Report for October

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the target of a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 840,899 shares, a growth of 539.6% from the September 30th total of 131,478 shares. Approximately 19.8% of the company’s shares are sold short. Based on an average daily volume of 28,786,521 shares, the short-interest ratio is currently 0.0 days.

Sunshine Biopharma Trading Up 22.0%

Shares of SBFM traded up $0.58 during trading hours on Tuesday, reaching $3.23. 190,822 shares of the company’s stock traded hands, compared to its average volume of 113,583. The firm’s 50 day simple moving average is $15.74 and its 200-day simple moving average is $114.66. Sunshine Biopharma has a 12 month low of $2.58 and a 12 month high of $464.00. The stock has a market cap of $13.94 million, a PE ratio of -0.32 and a beta of 1.20.

Sunshine Biopharma (NASDAQ:SBFM) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($23.00) earnings per share for the quarter, topping the consensus estimate of ($24.00) by $1.00. Sunshine Biopharma had a negative return on equity of 26.36% and a negative net margin of 17.94%. The company had revenue of $9.26 million for the quarter, compared to the consensus estimate of $8.70 million. As a group, analysts expect that Sunshine Biopharma will post -1.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Sunshine Biopharma to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings lowered Sunshine Biopharma from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, October 13th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce”.

About Sunshine Biopharma

Sunshine Biopharma, Inc is a pharmaceutical and biotechnology company focused on developing and commercializing therapies for cancer and other medical conditions. The company’s research pipeline has included Adva-27a, an anticancer compound designed to target tumors that may be resistant to existing treatments, as well as mRNA-based therapeutic candidates.

Through its Canadian operations, including Nora Pharma, Sunshine Biopharma is also involved in the development, marketing and distribution of prescription and over-the-counter pharmaceutical products.